Establishment and evaluation of a bead-based luminex assay allowing simultaneous quantification of equine IL-12 and IFN-γ.

The research focuses on developing an accurate method to simultaneously measure the levels of equine interleukin-12 (IL-12) and interferon gamma (IFN-γ), key elements in horse melanoma therapy. Using various antibodies and a Luminex bead-based assay, the study demonstrated the successful collection of these cytokines from biological samples.

Research Objective

• The main aim of this study was to create an accurate method that allows for the simultaneous quantification of equine IL-12 (eIL-12) and IFN-γ (eIFN-γ), two key cytokines involved in the immune-therapy of equine melanoma. Prior to this study, such a method was non-existent.

Methodology

• The researchers evaluated several antibodies for cross-reactivity to eIL-12 and eIFN-γ, using them to establish a Luminex bead-based assay.
• This assay was then utilized to quantify cytokine concentrations within biological samples.

Results

• The detection ranges for eIL-12 and eIFN-γ were 31.5-5,000 pg/ml and 15-10,000 pg/ml respectively.
• eIL-12 was detected in supernatants of stimulated peripheral blood mononuclear cells (PBMCs) and supernatants/cell lysates of eIL-12 expression plasmid-transfected cells.
• Low or undetectable cytokine concentrations were observed in negative control samples.
• In equine serum samples, the mean measured eIL-12 concentration was 1,374 ± 8 pg/ml.
• Comparisons made between the bead-based assay and ELISA for eIFN-γ used to measure eIFN-γ concentrations showed similar results.

Conclusion

• The researchers concluded that the use of cross-reactive antibody pairs to eIL-12 and eIFN-γ in conjunction with Luminex bead-based technology allows for the accurate, simultaneous, and multiplexed quantification of these vital cytokines in biological samples. This is believed to be the first demonstration of such a capacity.